FDA extends Aldeyra's reproxalap PDUFA date to March 2026 after a major NDA amendment tied to new clinical study report data.
In the second part, the discussion turns to emerging DED therapies that target tear function and ocular surface homeostasis.
Eyes with meibomian gland dysfunction are more likely to have increased tears and lower tear film stability, possible signs ...
Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden ...
GLP-1 receptor agonists are not associated with increased risks for dry age-related macular degeneration or cataract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback